波士顿科学Boston Scientific Corporation (BSX) 2024年年度报告「NYSE」.pdf

1、Boston Scientific 2024 Annual ReportSPINE ART2024 Annual Report Dear Stockholders:Our growth strategy at Boston Scientific over the past decade has focused on category leadership:to become the go-to company in the medical specialties we serve.Thanks to the unparalleled talent and commitment of our g

2、lobal teams,in 2024 we continued to see the results of that long-term strategy as we achieved one of the strongest years in our companys 45-year history.Working together,we moved from consistently outperforming our peers to becoming one of the highest-performing large cap companies in medtech.We fue

3、led our pipeline with acquisitions that add innovative high-growth products to our portfolio,launched approximately 100 products,generated new evidence through clinical trials,expanded our manufacturing and supply chain capacity to meet growing demand,and enhanced our digital and AI capabilities.Mos

4、t important,we helped improve the lives of more than 44 million patients around the world.While the companys biggest news of 2024 was our groundbreaking advancements for cardiology patients accomplishments I could not be prouder of theres so much more to report.When you look across our entire compan

5、y,youll find key growth drivers in all our businesses.The depth and breadth of our portfolio is the result of years of focus and discipline and puts Boston Scientific in a strong position for continued growth.These successes are possible because of the skills and values-driven efforts of our employe

6、es approximately 53,000 around the world.I am incredibly grateful for their dedication.2024 ResultsOur full-year net sales were$16.7 billion.This represents growth of 17.6 percent on a reported basis,18.5 percent on an operational1 basis and 16.4 percent on an organic2 basis compared to 2023.Our exc